Welcome to our dedicated page for Bio-Key Intl SEC filings (Ticker: BKYI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The BIO-key International, Inc. (NASDAQ: BKYI) SEC filings page provides direct access to the company’s regulatory disclosures, including annual and quarterly reports, current reports on Form 8-K, registration statements, and other key documents. These filings offer detailed insight into BIO-key’s identity and access management (IAM) and biometric authentication business, financial condition, risk factors, and capital markets activity.
In its S-1 registration statement, BIO-key outlines its role as an IAM platform provider for enterprise and large-scale customer and civil ID solutions. The filing describes the PortalGuard and PortalGuard IDaaS platforms, identity-bound biometrics, and the company’s biometric and authentication hardware portfolio. Investors can review this document to understand the structure of BIO-key’s business, its revenue sources from software licenses, services, and hardware, and its approach to large-scale biometric deployments.
Current reports on Form 8-K document material events such as financing transactions, warrant exercise agreements, secured promissory notes, Nasdaq listing compliance notices, and earnings announcements. For example, recent 8-K filings describe a warrant inducement transaction, a senior secured promissory note, and Nasdaq correspondence regarding the minimum bid price requirement for BKYI shares.
Through this page, users can also access proxy materials like the definitive proxy statement (DEF 14A), which covers matters submitted to shareholders, including director elections, auditor ratification, and equity compensation plans. These documents provide additional context on BIO-key’s governance and shareholder approvals.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents such as 10-Ks, 10-Qs, S-1s, and 8-Ks. Real-time updates from the SEC’s EDGAR system ensure that new filings appear promptly, while AI-generated overviews help readers quickly identify information on topics such as revenue composition, financing terms, listing status, and risk disclosures. Users can also review insider and major holder information through Forms 3, 4, and 5 when available, with AI explanations that clarify the significance of reported transactions.
Michael DePasquale, Chief Executive Officer and Director of Bio-Key International, Inc. (BKYI), amended a Form 4 to report two small open-market purchases. The filing shows purchases of 2,500 shares on 09/15/2025 at $0.75 and 1,617 shares on 09/16/2025 at $0.84, increasing his direct beneficial ownership to 102,775 shares. The amendment clarifies that this total excludes previously reported options to purchase 232 shares and warrants for 9,167 shares that were included in an earlier Form 4 filed the same day. The form is signed by Mr. DePasquale on 09/17/2025 and indicates the filing is by one reporting person.
Michael DePasquale, Chief Executive Officer and Director of Bio-Key International, Inc. (BKYI), reported two open-market purchases of the company's common stock. On 09/15/2025 he purchased 2,500 shares at $0.75 per share and on 09/16/2025 he purchased 1,617 shares at $0.84 per share. Following these transactions he beneficially owned 112,174 shares directly. The filing notes that reported holdings exclude options to purchase 232 shares and warrants exercisable into 9,167 shares. The Form 4 is signed and dated 09/17/2025.
Insider equity grant reported for BIO-key International, Inc. (BKYI). Cecilia C. Welch, the company's Chief Financial Officer and a director, was granted 35,000 restricted shares on 09/02/2025 at no cash price. The restricted stock vests in three equal annual installments on each anniversary of the grant date, subject to Ms. Welch's continued employment or service. Following the grant, Ms. Welch beneficially owns 59,396 shares, excluding an option to purchase 174 shares. The Form 4 is signed by Ms. Welch on 09/03/2025 and discloses the grant under the issuer's 2023 Stock Incentive Plan, as amended.
James D. Sullivan, a director and the Chief Legal Officer and SVP Strategy & Compliance of BIO-key International, Inc. (BKYI), reported a non‑derivative acquisition on 09/02/2025. He was granted 40,000 restricted shares under the company’s 2023 Stock Incentive Plan at a reported price of $0. Those restricted shares vest in three equal annual installments over the next three anniversaries of the grant date, subject to continued service. After the grant, Sullivan beneficially owns 94,851 shares (not including options to purchase 174 shares). The Form 4 was signed on 09/03/2025.
Mira LaCous, Chief Technology Officer of BIO-key International, Inc. (BKYI), was granted 25,000 restricted shares on 09/02/2025 under the company’s 2023 Stock Incentive Plan. The restricted shares vest in three equal annual installments on each of the next three anniversaries of the grant date, subject to her continued employment or service. The grant price is $0. Following the grant, Ms. LaCous beneficially owns 35,758 shares (this total excludes options to purchase 87 shares). The Form 4 was signed on 09/03/2025.
Bio-key International reported a grant of 45,000 restricted shares to Michael DePasquale, who serves as Chief Executive Officer and a director. The shares were awarded under the company's 2023 Stock Incentive Plan and vest in three equal annual installments over the next three anniversaries of the grant date, subject to continued service. Following the grant, the reporting person’s beneficial ownership is reported as 98,658 common shares; this total excludes options to purchase 232 shares.
BIO-key International, Inc. has filed a Form S-8 to register an additional 700,000 shares of its common stock for issuance under the BIO-key International, Inc. 2021 Employee Stock Purchase Plan, as amended. These shares are reserved for employees who participate in the plan.
The increase in the share pool was approved by the board of directors, upon recommendation of the Compensation Committee, on June 18, 2025, and subsequently approved and adopted by stockholders on August 8, 2025. The filing also notes that all figures related to the plan have been adjusted to reflect an 18-for-1 stock split effected on December 20, 2023, and incorporates a prior S-8 registration by reference.
BIO-key International, Inc. filed a Form S-8 to register an additional 700,000 shares of its common stock under the 2023 Stock Incentive Plan, as Amended. The board approved the increase on June 18, 2025 and stockholders adopted it on August 8, 2025. The filing incorporates a prior Form S-8 that registered 333,334 shares, and notes all figures reflect the 18-for-1 stock split effective December 20, 2023.
James D. Sullivan, listed as Chief Legal Officer and SVP Strategy & Compliance of BIO-key International, Inc. (BKYI), reported an open-market purchase of 10,000 shares of common stock on 08/22/2025 at a price of $0.77 per share. After the transaction he beneficially owned 54,851 shares directly; the reported holdings expressly exclude options to purchase 174 shares. The Form 4 indicates this was an individual filing by one reporting person and records the acquisition under transaction code "P." No derivatives or other types of securities were reported in this filing.
BIO-key International, Inc. held its Annual Meeting of Stockholders on August 8, 2025 where shareholders approved two plan amendments. The BIO-key 2023 Stock Incentive Plan was amended to increase the number of shares available for issuance by an additional 700,000 shares while remaining otherwise unchanged. The BIO-key 2021 Employee Stock Purchase Plan was likewise amended to increase available shares by an additional 700,000 shares and was unchanged aside from the share increase. The filing also lists the two amendment exhibits and an embedded Inline XBRL cover page data file.